MktsMarkets

NRX Pharmaceuticals, Inc.
NASDAQ: NRXPKey statistics
NRXP News
Stories mentioning NRXP from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 1,068 | 242.00 | 0.00 | 0.00 | ||||
| Cost of Goods Sold | 631.00 | 97.00 | 0.00 | 0.00 | ||||
| Gross Profit | 437.00 | 575.00 | 145.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 1,309 | 557.00 | 1,429 | 987.00 | 804.00 | 1,036 | 611.00 | 2,804 |
| Sales General & Admin | 3,813 | 2,808 | 2,943 | 2,409 | ||||
| Total Operating Expenses | 3,730 | 2,432 | 3,022 | 7,050 | ||||
| Operating Income (Loss) | (4,742) | (4,623) | (4,024) | (3,730) | (3,847) | (2,432) | (3,022) | (7,050) |
| Interest Income | 5.00 | 4.00 | 2.00 | 2.00 | 4.00 | 4.00 | 6.00 | 7.00 |
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | 0.00 | 0.00 | ||||||
| Net Income (Loss) | (1,430) | 361.00 | (5,890) | (17,581) | (5,512) | (9,078) | (1,623) | (7,897) |
| Earnings Per Share (Basic) | (0.04) | 0.02 | (0.27) | (0.98) | (0.34) | (0.85) | (0.15) | (0.75) |
| Earnings Per Share (Diluted) | ||||||||
| Weighted Average Shares Outstanding (Basic) | 32,325 | 21,402 | 22,231 | 17,934 | 16,410 | 10,644 | 10,974 | 10,517 |
| Weighted Average Shares Outstanding (Diluted) | ||||||||
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About NRXP
NRX Pharmaceuticals, Inc. (NASDAQ: NRXP) is a stock listed on the Nasdaq Stock Market under the ticker symbol NRXP. It last traded at $2.27 (Oct 30, 2026, 4:00 PM ET), down 14.7% on the day. That gives NRX Pharmaceuticals a market capitalisation of $98.3M.
Over the past 52 weeks NRXP has traded between $1.62 and $5.05.
Revenue for the quarter ended Mar 31, 2026 was $1.1M; a net loss of $1.4M.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $1.1M | -$1.4M | -133.9% |
| Dec 31, 2025 | — | $361.0K | — |
| Sep 30, 2025 | $242.0K | -$5.9M | -2433.9% |
| Jun 30, 2025 | — | -$17.6M | — |
From NRX Pharmaceuticals’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…